Form 4: ZyVersa Therapeutics Director Min-Chul Park Granted Stock Options

ZyVersa Therapeutics, Inc. Director Min-Chul Park was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.

Summary

• Min-Chul Park, a Director of ZyVersa Therapeutics, Inc. (ZVSA), was granted stock options.
• The grant date for these options was July 11, 2025.
• A total of 11,066 stock options were acquired.
• The exercise price for these options is $0.59 per share.
• The options vest in equal annual installments on the first three anniversaries of the grant date, contingent on continued service.
• The options expire on July 11, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns management incentives with shareholder interests, indicating a stable governance practice rather than a significant positive or negative operational development.

Positives

• The grant of stock options to Director Min-Chul Park aligns his interests with those of shareholders, incentivizing long-term performance and value creation for ZyVersa Therapeutics, Inc.

Negatives

• NA

Risks

• The value of the stock options is dependent on the future performance of ZyVersa Therapeutics, Inc.'s common stock, and there is no guarantee that the stock price will exceed the exercise price of $0.59.
• Vesting of the options is subject to the Director's continued service, meaning unvested options could be forfeited if service ceases.

Future Outlook

NA

Management Comments

• NA

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including for companies like ZyVersa Therapeutics, Inc., as a form of long-term incentive compensation to align leadership interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across various industries, including biotechnology, and is consistent with typical equity incentive plans designed to retain and motivate key personnel. The specific terms (exercise price, vesting schedule) would require comparison to peer companies of similar market capitalization and stage of development to assess their competitiveness, but such details are not provided in this filing.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Grant of 11,066 stock options to Min-Chul Park, a Director of ZyVersa Therapeutics, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align management's interests with shareholders, potentially leading to increased long-term value if the options are exercised due to stock price appreciation. However, it also represents potential future dilution if the options are exercised.

Next Steps

• Continued service of Min-Chul Park as a Director of ZyVersa Therapeutics, Inc.
• Annual vesting of stock options on the first three anniversaries of July 11, 2025.
• Potential exercise of vested stock options by Min-Chul Park before July 11, 2035.

Key Dates

Keywords

ZyVersa Therapeutics, ZVSA, stock options, director compensation, equity grant, beneficial ownership, Form 4, insider transaction